NICE to consider lenalidomide maintenance treatment for myeloma patients post high dose therapy and stem cell transplantation
Lenalidomide (Revlimid®) maintenance for myeloma patients who have undergone high dose therapy and stem cell transplantation (HDT-SCT) will be considered for use on the NHS by The National Institute for Health and Care Excellence (NICE) later this year. This announcement comes after updated advice from the manufacturer Celgene and follows publication of data from the Myeloma XI clinical…